On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Mixed Results in Trials of Momelotinib Versus Ruxolitinib for Myelofibrosis

The investigational JAK1/2 inhibitor momelotinib was active in the treatment of myelofibrosis (MF) in phase I/II trials, but updates presented at the 2017 ASCO...

BFORE Trial: Bosutinib Could Be a “Welcome” New Treatment Option for Chronic-Phase CML

Treatment with the dual SRC/ABL tyrosine kinase inhibitor bosutinib was associated with a higher major molecular response (MMR), deeper response, and shorter time to...

Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy Is Safe, Effective in Older Patients With ALL

In February 2017, the U.S. Food and Drug Administration granted inotuzumab ozogamicin priority review for the treatment of adult patients with relapsed/refractory B-cell precursor...

Early Results from CAR T-Cell Therapy Trial for Myeloma Show “Encouraging” Response Rates

In an ongoing, phase I trial of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory myeloma, 33 out of 35 patients achieved...

Minimizing VTE Risk in Myeloma Patients Receiving Immunomodulators

Patients with myeloma who receive treatment with immunomodulatory drugs (IMIDs) such as lenalidomide and thalidomide have an increased risk of venous thromboembolism (VTE), but...

Is Denosumab a Safer Alternative to Zoledronic Acid in Newly Diagnosed Myeloma?

Patients with multiple myeloma (MM) can experience osteolytic bone disease that is typically treated with zoledronic acid (ZA) – which can be nephrotoxic. Denosumab...

Investigating an Elotuzumab-Based Quadruplet Combination in Newly Diagnosed Myeloma

In results from a phase IIa trial presented at the 2017 ASCO Annual Meeting, adding the anti-SLAMF7 monoclonal antibody elotuzumab to the three-drug combination...

Bendamustine Plus Rituximab “StiL” Better Than R-CHOP for Improving Survival in Indolent Lymphomas

Earlier results from the randomized, phase III StiL trial of patients with indolent lymphomas demonstrated that the combination of bendamustine plus rituximab (BR) led...

Ublituximab Plus Ibrutinib Improves Objective Response Rates in High-Risk CLL

Patients with chronic lymphocytic leukemia (CLL) and high-risk genetic mutations typically have poor response to ibrutinib monotherapy, but adding ublituximab, a novel anti-CD20 monoclonal...

Daratumumab-Based Quadruplet Combination Is Safe in Newly Diagnosed Myeloma

In November 2016, the U.S. Food and Drug Administration approved the anti-CD38 monoclonal antibody daratumumab in combination with two standard-of-care regimens (dexamethasone plus lenalidomide...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.